170 related articles for article (PubMed ID: 27603498)
1. The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States.
Latremouille-Viau D; Chang J; Guerin A; Shi S; Wang E; Yu J; Ngai C
J Med Econ; 2017 Jan; 20(1):54-62. PubMed ID: 27603498
[TBL] [Abstract][Full Text] [Related]
2. Adverse event-related costs for systemic metastatic breast cancer treatment among female Medicaid beneficiaries.
Irwin DE; Masaquel A; Johnston S; Barnett B
J Med Econ; 2016 Nov; 19(11):1027-1033. PubMed ID: 27206801
[TBL] [Abstract][Full Text] [Related]
3. Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer.
Yang H; Yu AP; Wu EQ; Yim YM; Yu E
J Med Econ; 2011; 14(5):542-52. PubMed ID: 21728912
[TBL] [Abstract][Full Text] [Related]
4. Costs associated with adverse events during treatment episodes for adult attention-deficit/hyperactivity disorder.
Schein J; Cloutier M; Bungay R; Gauthier-Loiselle M; Childress A
J Med Econ; 2024; 27(1):653-662. PubMed ID: 38602691
[TBL] [Abstract][Full Text] [Related]
5. Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer.
Engel-Nitz NM; Johnson MP; Bunner SH; Ryan KJ
J Manag Care Spec Pharm; 2020 Jun; 26(6):729-740. PubMed ID: 32463768
[TBL] [Abstract][Full Text] [Related]
6. Costs of adverse events among patients with HIV infection treated with nonnucleoside reverse transcriptase inhibitors.
Simpson KN; Chen SY; Wu AW; Boulanger L; Chambers R; Nedrow K; Tawadrous M; Pashos CL; Haider S
HIV Med; 2014 Sep; 15(8):488-98. PubMed ID: 24641448
[TBL] [Abstract][Full Text] [Related]
7. Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting.
Hurvitz S; Guerin A; Brammer M; Guardino E; Zhou ZY; Latremouille Viau D; Wu EQ; Lalla D
Oncologist; 2014 Sep; 19(9):901-8. PubMed ID: 25085897
[TBL] [Abstract][Full Text] [Related]
8. Assessment of costs associated with adverse events in patients with cancer.
Wong W; Yim YM; Kim A; Cloutier M; Gauthier-Loiselle M; Gagnon-Sanschagrin P; Guerin A
PLoS One; 2018; 13(4):e0196007. PubMed ID: 29652926
[TBL] [Abstract][Full Text] [Related]
9. Real-world incidence and burden of adverse events among non-metastatic prostate cancer patients treated with secondary hormonal therapies following androgen deprivation therapy.
Shah A; Shah R; Kebede N; Mohamed A; Botteman M; Waldeck R; Hussain A
J Med Econ; 2020 Apr; 23(4):330-346. PubMed ID: 31835965
[No Abstract] [Full Text] [Related]
10. Real-world Direct Health Care Costs for Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab-containing Regimens in First-line or First-line Through Second-line Therapy.
Johnston S; Wilson K; Varker H; Malangone-Monaco E; Juneau P; Riehle E; Satram-Hoang S; Sommer N; Ogale S
Clin Colorectal Cancer; 2017 Dec; 16(4):386-396.e1. PubMed ID: 28619608
[TBL] [Abstract][Full Text] [Related]
11. Comparative net cost impact of the utilization of panitumumab versus cetuximab for the treatment of patients with metastatic colorectal cancer in Canada.
Pettigrew M; Kavan P; Surprenant L; Lim HJ
J Med Econ; 2016; 19(2):135-47. PubMed ID: 26442575
[TBL] [Abstract][Full Text] [Related]
12. Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy.
Hao Y; Li N; Fang AP; Koo V; Peeples M; Kageleiry A; Wu EQ; Guérin A
Adv Ther; 2016 Jun; 33(6):983-97. PubMed ID: 27216253
[TBL] [Abstract][Full Text] [Related]
13. Economic burden associated with adverse events in patients with metastatic melanoma.
Arondekar B; Curkendall S; Monberg M; Mirakhur B; Oglesby AK; Lenhart GM; Meyer N
J Manag Care Spec Pharm; 2015 Feb; 21(2):158-64. PubMed ID: 25615005
[TBL] [Abstract][Full Text] [Related]
14. Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy.
Borghaei H; Yim YM; Guerin A; Pivneva I; Shi S; Gandhi M; Ionescu-Ittu R
Lung Cancer; 2018 May; 119():112-119. PubMed ID: 29656745
[TBL] [Abstract][Full Text] [Related]
15. Economic burden of toxicities associated with metastatic colorectal cancer treatment regimens containing monoclonal antibodies.
Burudpakdee C; Zhao Z; Munakata J; Gao S; Trochlil K; Barber B
J Med Econ; 2012; 15(2):371-7. PubMed ID: 22181051
[TBL] [Abstract][Full Text] [Related]
16. Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis.
Li N; Hao Y; Koo V; Fang A; Peeples M; Kageleiry A; Wu EQ; Guérin A
J Med Econ; 2016; 19(4):414-23. PubMed ID: 27032967
[TBL] [Abstract][Full Text] [Related]
17. Costs associated with adverse events in patients with metastatic renal cell carcinoma.
Borker R
J Med Econ; 2014 Nov; 17(11):792-7. PubMed ID: 25116694
[TBL] [Abstract][Full Text] [Related]
18. Cost and economic burden of adverse events associated with metastatic melanoma treatments in five countries.
Vouk K; Benter U; Amonkar MM; Marocco A; Stapelkamp C; Pfersch S; Benjamin L
J Med Econ; 2016 Sep; 19(9):900-12. PubMed ID: 27123564
[TBL] [Abstract][Full Text] [Related]
19. Healthcare resource utilization and costs of adverse events among patients with metastatic urothelial cancer in USA.
Grivas P; DerSarkissian M; Shenolikar R; Laliberté F; Doleh Y; Duh MS
Future Oncol; 2019 Nov; 15(33):3809-3818. PubMed ID: 31596144
[No Abstract] [Full Text] [Related]
20. Service setting impact on costs for bevacizumab-treated oncology patients.
Engel-Nitz NM; Yu EB; Becker LK; Small A
Am J Manag Care; 2014 Nov; 20(11):e515-22. PubMed ID: 25730350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
